Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Alzheimer's disease: basic aspects].

T Iwatsubo1

  • 1Department of Neuropathology and Neuroscience, Graduate School of Pharmaceutical Sciences, University of Tokyo.

Nihon Ronen Igakkai Zasshi. Japanese Journal of Geriatrics
|July 6, 2000
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Japanese Subgroup Analyses from EMERGE and ENGAGE, Phase 3 Clinical Trials of Aducanumab in Patients with Early Alzheimer's Disease.

The journal of prevention of Alzheimer's disease·2024
Same author

Usability of a Web-Based Registry for Preclinical Alzheimer's Disease: Implications from a Cross-Sectional Online Survey.

The journal of prevention of Alzheimer's disease·2024
Same author

Editorial: Clinical Implementation of Lecanemab: Challenges, Questions and Solutions.

The journal of prevention of Alzheimer's disease·2023
Same author

Investigating Partially Discordant Results in Phase 3 Studies of Aducanumab.

The journal of prevention of Alzheimer's disease·2023
Same author

Two Randomized Phase 3 Studies of Aducanumab in Early Alzheimer's Disease.

The journal of prevention of Alzheimer's disease·2022
Same author

Therapeutic Targets for Alzheimer's Disease: Amyloid Vs. Non-Amyloid. Where Does Consensus Lie Today? An CTAD Task Force Report.

The journal of prevention of Alzheimer's disease·2022
Same journal

[[Overview] Current status and challenges of ACP for older adults].

Nihon Ronen Igakkai zasshi. Japanese journal of geriatrics·2026
Same journal

[Preface to the special issue on "Efforts for better advance care planning for older adults - Current situation and challenges in Japan"].

Nihon Ronen Igakkai zasshi. Japanese journal of geriatrics·2026
Same journal

[Japan-multimodal intervention trial for prevention of dementia (J-MINT) and its societal implementation: Concepts, challenges, and future directions].

Nihon Ronen Igakkai zasshi. Japanese journal of geriatrics·2026
Same journal

[Frontlines in geriatrics: Polypharmacy, the key revisions of the 2025 guidelines for medical treatment and its safety in the elderly].

Nihon Ronen Igakkai zasshi. Japanese journal of geriatrics·2026
Same journal

[Erratum].

Nihon Ronen Igakkai zasshi. Japanese journal of geriatrics·2026
Same journal

Nihon Ronen Igakkai zasshi. Japanese journal of geriatrics·2026
See all related articles

Amyloid beta 42 (A beta 42) peptides are key in Alzheimer's disease (AD) pathogenesis. Genetic mutations affecting beta amyloid precursor protein (beta APP) and presenilins (PS) influence A beta 42 levels, highlighting its central role in AD development.

Area of Science:

  • Neuroscience
  • Genetics
  • Molecular Biology

Context:

  • Alzheimer's disease (AD) is characterized by amyloid beta (A beta) peptide deposition.
  • A beta peptides, particularly the 42-amino acid variant (A beta 42), are implicated in early AD pathology.
  • Mutations in beta amyloid precursor protein (beta APP) and presenilin (PS) genes are linked to familial AD (FAD).

Purpose:

  • To elucidate the role of A beta 42 in Alzheimer's disease pathogenesis.
  • To investigate the impact of genetic mutations on A beta 42 production and deposition.
  • To explore the function of presenilin 1 (PS1) in protein cleavage pathways relevant to AD.

Summary:

  • Amyloid beta (A beta) peptides, especially A beta 42, are central to Alzheimer's disease (AD) pathology.

Related Experiment Videos

  • Mutations in beta amyloid precursor protein (beta APP) and presenilin (PS1/PS2) genes increase A beta 42 secretion and deposition, supporting its pathogenic role.
  • Presenilin 1 (PS1) acts as a coactivator for beta APP gamma-cleavage, and tau gene mutations are linked to neurodegenerative dementia (FTDP-17).

    • Impact:

    • Understanding the genetic basis and protein aggregation mechanisms in AD and related disorders.
    • Provides insights into the early pathological changes in Alzheimer's disease.
    • Facilitates the development of targeted therapeutic strategies for AD and neurodegenerative diseases.